5-HT NEURONS AND MEAL REGULATION
5-HT 神经元和膳食调节
基本信息
- 批准号:10678539
- 负责人:
- 金额:$ 6.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:Action PotentialsAgonistAmericanAnimalsAreaBody WeightBody Weight decreasedBrainConsumptionDRD2 geneDataDevelopmentDiabetes MellitusDopamineDopamine D2 ReceptorDopamine ReceptorEatingElectrophysiology (science)Energy IntakeEnergy MetabolismEnzymesFeeding behaviorsFellowshipFenfluramineFiberFoodFood Intake RegulationFunctional disorderGABA ReceptorGoalsHealthHomeostasisHungerHyperphagiaHypertensionHypothalamic structureInfectionInstitutionIntakeLearningLong-Term PotentiationMediatingMedicineMembrane PotentialsMental DepressionMetabolicModelingMoodsMusNeural PathwaysNeuronsNon-Insulin-Dependent Diabetes MellitusNutritionalObesityOutcomeOverweightPatternPharmaceutical PreparationsPhotometryPhysiologicalPlayPrevalencePropertyProtocols documentationRegimenRegulationResearchResourcesRestRiskRoleSARS-CoV-2 infectionSatiationScientistSerotoninSignal TransductionStructure of nucleus infundibularis hypothalamiSystemTPH2TestingTherapeuticTrainingWild Type MouseWorkbody systemcancer riskcareercollegecomorbiditycomparison controldorsal raphe nucleusenergy balancefeedinggamma-Aminobutyric Acidglobal healthimprovedneurobiological mechanismneurotransmissionnew therapeutic targetnovelobese personobesity preventionoptogeneticspostsynapticpreventreceptorreduced food intakeresponseside effectsuccesstherapeutic developmenttherapeutically effectivetool
项目摘要
PROJECT SUMMARY
Despite the rapidly growing rate in obesity and tremendous efforts in weight loss research, the development of
safe and effective therapeutics has progressed significantly, yet is still limited, largely due to insufficient
understanding of how the brain manages body weight and feeding. Lorcaserin, a 5-HT (serotonin) receptor
agonist, showed great promise for effectively reducing weight, but was withdrawn due to increased risk for cancer
development. 5-HT remains an excellent potential target for an anti-obesity therapeutic, but more work needs to
be completed to determine the most effective way for targeting 5-HT. Previous work in this area has shown that
GABA and dopamine inhibition of 5-HT neurons is critical for mediating food intake in mice. In fact, my preliminary
work has revealed that 2 (GABA receptor subunit) deletion in TPH2 (rate limiting enzyme for 5-HT synthesis)
neurons causes a decreased meal number and increased meal interval compared to wild-type mice, indicating
a potential dysfunction in meal initiation. Furthermore, DRD2 (a dopamine receptor) deletion reduced miniature
inhibitory post synaptic current (mIPSC) in TPH2 neurons, indicating that DRD2 plays an essential role in
mediating 5-HT neuronal response to GABA inhibitory input. Finally, I found that in hungry mice, the selective
activation of 5-HT neurons in the Dorsal Raphe Nucleus (DRN) which project to the Arcuate Nucleus (ARH) in
the Hypothalamus during food approach significantly reduces food intake compared to control mice. Taken
together, these preliminary data led me to the hypothesis that GABA inputs to 5-HTDRN neurons are regulated, in
part, by DRD2 and may contribute to the regulation of meal initiation. The focus of this proposal is to 1) determine
whether the 5-HTDRN→ARH circuit regulates meal initiation and 2) to determine whether DA influences GABA
signaling to ARH-projecting 5-HTDRN neurons for meal initiation. To achieve these goals, I will examine (1)
whether photostimulation or photoinhibition of the 5-HTDRN→ARH circuit during food approach alters meal
initiation and food intake, and (2) the dynamic activity of ARH-projecting 5-HTDRN neurons before or during food
approach, at meal initiation, eating and meal termination using fiber photometry. Further, I will generate mice
with a selective deletion of either the GABAA γ2 subunit or DA receptor DRD2 in ARH-projecting 5-HTDRN neurons
and perform metabolic and meal pattern studies, and (2) examine the electrophysiological properties (mIPSC,
resting membrane potential, action potential firing, and their responses to GABA or DRD2 agonists) of ARH-
projecting 5-HTDRN neurons in which either the GABAA γ2 subunit or DA receptor DRD2 is deleted. With support
from this fellowship, I will utilize the extensive resources at Baylor College of Medicine to expand my expertise
so that I can advance in my career and learn more novel and comprehensive approaches to studying the
mechanisms underlying meal initiation. This opportunity will provide me with the necessary tools to enhance my
training and move toward my career goal of becoming an independent research scientist at an academic
institution.
项目总结
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Unraveling the serotonin saga: from discovery to weight regulation and beyond - a comprehensive scientific review.
- DOI:10.1186/s13578-023-01091-7
- 发表时间:2023-08-07
- 期刊:
- 影响因子:7.5
- 作者:Conde, Kristine;Fang, Shuzheng;Xu, Yong
- 通讯作者:Xu, Yong
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kristine Marie McDermott其他文献
Kristine Marie McDermott的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 6.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 6.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 6.95万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 6.95万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 6.95万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 6.95万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 6.95万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 6.95万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 6.95万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 6.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)